Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Atossa Genetics Inc. (NASDAQ:ATOS) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.85 and traded as low as $0.70. Atossa Genetics shares last traded at $0.7147, with a volume of 2,877,072 shares traded.

Analysts Set New Price Targets

Several equities analysts have issued reports on ATOS shares. Zacks Research lowered Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Ascendiant Capital Markets raised their price target on shares of Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a report on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.33.

Atossa Genetics Price Performance

The firm has a market cap of $92.32 million, a price-to-earnings ratio of -2.98 and a beta of 0.95. The firm has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $0.85.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). Equities analysts anticipate that Atossa Genetics Inc. will post -0.22 earnings per share for the current fiscal year.

Institutional Trading of Atossa Genetics

Several large investors have recently added to or reduced their stakes in ATOS. Y Intercept Hong Kong Ltd acquired a new stake in shares of Atossa Genetics during the second quarter worth about $321,000. Charles Schwab Investment Management Inc. raised its position in Atossa Genetics by 40.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company’s stock worth $284,000 after buying an additional 120,934 shares during the last quarter. Nuveen LLC acquired a new stake in Atossa Genetics during the 1st quarter valued at approximately $115,000. Squarepoint Ops LLC boosted its holdings in shares of Atossa Genetics by 39.9% in the 3rd quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock valued at $220,000 after acquiring an additional 72,235 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Atossa Genetics by 55.8% in the third quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock worth $135,000 after acquiring an additional 55,568 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.